Results 91 to 100 of about 45,526 (248)
Multifaceted Approach to the Treatment of Bcr-Abl-Positive Leukemias
The Oncologist, 2002 Abstract Learning Objectives After taking all of the CME courses in this supplement the reader will be able to: Describe the basic biology of various leukemias, multiple myeloma, and myelodysplastic syndrome (MDS).
openaire +2 more sources
Neuropsychopharmacology Reports, Volume 46, Issue 1, March 2026.We analyzed the behavior of GPR143 gene‐deficient mice. GPR143‐KO mice displayed a mixed psychiatric phenotype. GPR143 may play a role in mesolimbic and mesocortical functions underlying sensory gating, reward, social hierarchy, cognition, and emotional regulation. ABSTRACT GPR143, originally identified as the gene product of ocular albinism 1 (OA1), a
Yoshio Goshima +9 more
wiley +1 more source
V280G Mutation, Potential Role in Imatinib Resistance: First Case Report
Clinical Medicine Insights: Oncology, 2017 Introduction: The identification of BCR-ABL expression as the defining leukemogenic event in chronic myeloid leukemia (CML) and the introduction of BCR-ABL tyrosine kinase inhibitors in 2001 have revolutionized disease management, leading to a reduction ...
Ana P Azevedo +5 more
doaj +1 more source
BMC Cancer, 2004 Background Based on the site of breakpoint in t(9;22) (q34;q11), bcr-abl fusion in leukemia patients is associated with different types of transcript proteins.
Cano Pedro +2 more
doaj +1 more source
Oncogenic stress induced by acute hyper-activation of Bcr-Abl leads to cell death upon induction of excessive aerobic glycolysis. [PDF]
PLoS ONE, 2011 In response to deregulated oncogene activation, mammalian cells activate disposal programs such as programmed cell death. To investigate the mechanisms behind this oncogenic stress response we used Bcr-Abl over-expressing cells cultivated in presence of ...
Michael A Dengler +8 more
doaj +1 more source
Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival [PDF]
, 2012 Recent evidence suggests CML stem cells are insensitive to kinase inhibitors and responsible for minimal residual disease in treated patients. We investigated whether CML stem cells, in a transgenic mouse model of CML-like disease or derived from ...
Anderson +61 more
core +2 more sources
Clinical Pharmacology in Drug Development, Volume 15, Issue 2, February 2026.Abstract Asciminib is the first BCR::ABL1 inhibitor that Specifically Targets the ABL Myristoyl Pocket (STAMP) in patients with chronic myeloid leukemia. This phase 1, two‐treatment‐period, drug‐drug interaction study evaluated the effect of steady‐state asciminib on the pharmacokinetics of atorvastatin.
Matthias Hoch +9 more
wiley +1 more source
Long circulating lectin conjugated paclitaxel loaded magnetic nanoparticles: a new theranostic avenue for leukemia therapy. [PDF]
PLoS ONE, 2011 Amongst all leukemias, Bcr-Abl positive chronic myelogenous leukemia (CML) confers resistance to native drug due to multi drug resistance and also resistance to p53 and fas ligand pathways.
Abhalaxmi Singh +2 more
doaj +1 more source
Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain [PDF]
, 2013 In chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia, tyrosine kinase inhibitor (TKI) therapy may select for drug-resistant BCR-ABL mutants. We used an ultra-deep sequencing (UDS) approach to resolve qualitatively
2. Soverini S +25 more
core +1 more source
eJHaem, Volume 7, Issue 1, February 2026.Abstract Background Immunophenotypically defined mixed‐phenotype acute leukemias (MPAL) are rare and remain a diagnostic and therapeutic dilemma. We aim to explore the clinicopathologic characteristics and oncological outcomes of these entities. Methods A total of 52 patients with immunophenotypically defined MPAL were identified from our pathology ...
Bo Zhang +5 more
wiley +1 more source